Clinical Trial Update: Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of docetaxel and S-1 in head and neck squamous cell carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: TERMINATED